Veteran private equity and growth investor with a background in healthcare and technology deals, focused on value-oriented buyouts, growth equity and operational improvement. Brian Runkles is known for sourcing cross-border carve-outs, leading board-level strategy and driving EBITDA expansion through commercial scaling and cost discipline. Experience spans portfolio operational oversight, capital structuring and exits via strategic sales and IPOs, appealing to limited partners seeking active governance and sector specialization.
Veteran private equity and growth investor with a background in healthcare and technology deals, focused on value-oriented buyouts, growth equity and operational improvement. Brian Runkles is known for sourcing cross-border carve-outs, leading board-level strategy and driving EBITDA expansion through commercial scaling and cost discipline. Experience spans portfolio operational oversight, capital structuring and exits via strategic sales and IPOs, appealing to limited partners seeking active governance and sector specialization.
Focuses on value-oriented buyouts and growth equity in healthcare and technology, favoring cross-border carve-outs and complex corporate divestitures. Investment style emphasizes operational improvement and commercial scaling to drive EBITDA expansion, with active board governance and hands-on portfolio oversight. Capital allocation favors disciplined leverage and staged capital deployment, aligning incentives for exits via strategic sale or IPO. Strategy prioritizes sector specialization, margin expansion, and repeatable playbooks that de-risk mid-term value creation.
Focuses on value-oriented buyouts and growth equity in healthcare and technology, favoring cross-border carve-outs and complex corporate divestitures. Investment style emphasizes operational improvement and commercial scaling to drive EBITDA expansion, with active board governance and hands-on portfolio oversight. Capital allocation favors disciplined leverage and staged capital deployment, aligning incentives for exits via strategic sale or IPO. Strategy prioritizes sector specialization, margin expansion, and repeatable playbooks that de-risk mid-term value creation.
| Trades 667 | Longs Won 494/667 74% | Profit Factor 18.28 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $346,349.34 |
| Average Win $94,187.23 | Best Trade (Aug 15) $7.17M | Sharpe Ratio -53.73 |
| Average Loss -$14,711.55 | Worst Trade (Mar 31) -$363,923.12 | Z-Score 14.15 (100%) |
| Commissions $0 | Avg. Trade Length 11m 4d | Expectancy $65,946.1 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 15,873 | 14,286 | 12,698 | 11,111 | 9,524 | 7,937 | 6,349 | 4,762 | 3,175 | 1,587 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 18,672 | $4.61M | $5.71M | - | $1.11M | 24.01% | +0.219% |
ABBV AbbVie Inc. | 2,338 | $441,315.89 | $583,237.5 | - | $141,921.61 | 32.16% | -0.542% |
ACWI iShares MSCI ACWI ETF | 2,106 | $274,485.54 | $341,782.72 | - | $67,297.18 | 24.52% | -0.117% |
AIRR First Trust RBA American Industrial Renaissance ETF | 127,802 | $9.5M | $15.94M | - | $6.44M | 67.81% | +1.604% |
AMD Advanced Micro Devices, Inc. | 735 | $426,838 | $378,076.66 | - | -$48,761.34 | -11.42% | +6.497% |
AMZN Amazon.com Inc | 6,272 | $1.37M | $1.65M | - | $278,079.71 | 20.31% | -0.935% |
AOA iShares Core Aggressive Allocation ETF | 4,834 | $379,237.15 | $482,143.16 | - | $102,906.01 | 27.14% | -0.15% |
APH Amphenol Corporation | 2,888 | $254,614.74 | $241,306.84 | - | -$13,307.9 | -5.23% | +0.821% |
ASML ASML Holding N.V. New York Registry Shares | 124 | $247,057 | $228,665.91 | - | -$18,391.09 | -7.44% | -0.207% |
AVGO Broadcom Inc. | 2,289 | $725,083.16 | $899,554.09 | - | $174,470.93 | 24.06% | -5.943% |
AXP American Express Company | 604 | $204,360 | $206,857.93 | - | $2,497.93 | 1.22% | -0.34% |
AZN AstraZeneca PLC American Depositary Shares | 2,144 | $406,507 | $335,428.8 | - | -$71,078.2 | -17.49% | -0.502% |
BAC Bank of America Corporation | 7,387 | $329,495.97 | $476,387.63 | - | $146,891.66 | 44.58% | +0.624% |
BBUS JPMorgan Betabuilders U.S. Equity Fund | 1,684 | $188,473.24 | $235,945.24 | - | $47,472 | 25.19% | -0.207% |
BRK-B Berkshire Hathaway Inc. | 606 | $290,777.01 | $305,442.18 | - | $14,665.17 | 5.04% | -0.572% |
BUFR FT Vestladder Buffer ETF-USD I | 317,634 | $9.85M | $11.89M | - | $2.04M | 20.73% | 0.0 |
CIBR First Trust NASDAQ Cybersecurity ETF | 2,941 | $264,272 | $292,923.6 | - | $28,651.6 | 10.84% | -2.544% |
COF Capital One Financial Corporation | 2,762 | $530,169.21 | $627,913.08 | - | $97,743.87 | 18.44% | +1.568% |
DE Deere & Company | 979 | $416,004.35 | $596,064.13 | - | $180,059.78 | 43.28% | -0.576% |
DOV Dover Corporation | 1,591 | $301,479.86 | $329,448.38 | - | $27,968.52 | 9.28% | +0.198% |